Floatz logo

mln9708

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma

Northwestern UniversityPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
University of California, Davis
Phase 2BB
Cytosin-Arabinosid
University of California, Davis
Phase 2B
Solu-Cortef
Northwestern University
Phase 1/2CCC
METHOTREXATE
Northwestern University
Phase 1/2CCC
Cediranib
Mayo Clinic
Phase 1CC
Pomalidomide
Mayo Clinic
Phase 1CC

Same molecule, other indications

mln9708 is also rated in:

Multiple MyelomaDormant
BB
Indicative ·
66 / 100
View asset →
AmyloidosisDormant
BB
Indicative ·
64 / 100
View asset →
Higher-risk Myelodysplastic SyndromeDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →